218 related articles for article (PubMed ID: 11672577)
41. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells.
Germain N; Boichot E; Advenier C; Berdyshev EV; Lagente V
Int Immunopharmacol; 2002 Mar; 2(4):537-43. PubMed ID: 11962732
[TBL] [Abstract][Full Text] [Related]
42. First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.
Benamar K; Geller EB; Adler MW
J Pharmacol Exp Ther; 2008 May; 325(2):641-5. PubMed ID: 18281594
[TBL] [Abstract][Full Text] [Related]
43. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.
Wallace MJ; Wiley JL; Martin BR; DeLorenzo RJ
Eur J Pharmacol; 2001 Sep; 428(1):51-7. PubMed ID: 11779037
[TBL] [Abstract][Full Text] [Related]
44. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
45. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
46. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat.
Coruzzi G; Adami M; Coppelli G; Frati P; Soldani G
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):715-8. PubMed ID: 10619190
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens.
Pertwee RG; Griffin G; Lainton JA; Huffman JW
Eur J Pharmacol; 1995 Sep; 284(3):241-7. PubMed ID: 8666005
[TBL] [Abstract][Full Text] [Related]
49. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.
Aceto MD; Scates SM; Martin BB
Eur J Pharmacol; 2001 Mar; 416(1-2):75-81. PubMed ID: 11282115
[TBL] [Abstract][Full Text] [Related]
50. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
51. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.
Mendiguren A; Pineda J
Eur J Pharmacol; 2006 Mar; 534(1-3):83-8. PubMed ID: 16483566
[TBL] [Abstract][Full Text] [Related]
52. Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.
Richter A; Löscher W
Eur J Pharmacol; 2002 Nov; 454(2-3):145-51. PubMed ID: 12421641
[TBL] [Abstract][Full Text] [Related]
53. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.
Kim SH; Won SJ; Mao XO; Jin K; Greenberg DA
Mol Pharmacol; 2006 Mar; 69(3):691-6. PubMed ID: 16299067
[TBL] [Abstract][Full Text] [Related]
54. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
55. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits.
Niederhoffer N; Szabo B
J Pharmacol Exp Ther; 2000 Aug; 294(2):707-13. PubMed ID: 10900251
[TBL] [Abstract][Full Text] [Related]
56. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats.
Tyler K; Hillard CJ; Greenwood-Van Meerveld B
Eur J Pharmacol; 2000 Dec; 409(2):207-11. PubMed ID: 11104836
[TBL] [Abstract][Full Text] [Related]
58. Influence of the CB(1) receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats.
Gardiner SM; March JE; Kemp PA; Bennett T
Br J Pharmacol; 2002 Jun; 136(4):581-7. PubMed ID: 12055136
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
Sánchez C; de Ceballos ML; Gomez del Pulgar T; Rueda D; Corbacho C; Velasco G; Galve-Roperh I; Huffman JW; Ramón y Cajal S; Guzmán M
Cancer Res; 2001 Aug; 61(15):5784-9. PubMed ID: 11479216
[TBL] [Abstract][Full Text] [Related]
60. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
